"ritlecitinib" meaning in English

See ritlecitinib in All languages combined, or Wiktionary

Noun

Head templates: {{en-noun|-}} ritlecitinib (uncountable)
  1. (pharmacology) A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata. Tags: uncountable Categories (topical): Pharmaceutical drugs
    Sense id: en-ritlecitinib-en-noun-IF-xz2K7 Categories (other): English entries with incorrect language header Topics: medicine, pharmacology, sciences

Download JSON data for ritlecitinib meaning in English (1.8kB)

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ritlecitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Fundamental"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173",
          "text": "Ritlecitinib is an irreversible covalent inhibitor that binds to a distinct cysteine residue in the JAK3 catalytic domain, which other JAK family members lack. […] Ritlecitinib was found to be superior to placebo in a phase II study in RA patients with an inadequate response to MTX (76).",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "id": "en-ritlecitinib-en-noun-IF-xz2K7",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Tec",
          "Tec"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "alopecia areata",
          "alopecia areata"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ritlecitinib"
}
{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ritlecitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173",
          "text": "Ritlecitinib is an irreversible covalent inhibitor that binds to a distinct cysteine residue in the JAK3 catalytic domain, which other JAK family members lack. […] Ritlecitinib was found to be superior to placebo in a phase II study in RA patients with an inadequate response to MTX (76).",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Tec",
          "Tec"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "alopecia areata",
          "alopecia areata"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ritlecitinib"
}

This page is a part of the kaikki.org machine-readable English dictionary. This dictionary is based on structured data extracted on 2024-06-04 from the enwiktionary dump dated 2024-05-02 using wiktextract (e9e0a99 and db5a844). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.

If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.